Nimodipine Tablets

Nimodipine is a Ca2 channel blocker. Under normal circumstances, the contraction of smooth muscle depends on Ca2 entering the cell, causing the depolarization of the transmembrane current. Nimodipine achieves the purpose of relieving vasospasm by effectively preventing Ca2 from entering the cell and inhibiting smooth muscle contraction. Animal experiments have shown that the effect of nimodipine on cerebral arteries is much stronger than that on arteries in other parts of the body, and because it has a high lipophilic characteristic, it can easily pass through the blood-brain barrier. When used to treat subarachnoid hemorrhage, the concentration in cerebrospinal fluid can reach 12.5ng/ml. It can be inferred that it can be used clinically to prevent vasospasm after subarachnoid hemorrhage, but the mechanism of action of this drug in humans is still unclear. In addition, it also has the function of protecting and promoting memory

The main ingredient of this product is nimodipine. Its chemical name is 1-methylethyl-2-methoxyethyl, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate.

This product is light yellow tablet.

Calcium channel blockers are used for ischemic cerebrovascular disease, migraine, cerebral vasospasm caused by mild subarachnoid hemorrhage, sudden deafness, and mild to moderate hypertension.

Take as follows, or follow the doctor's advice. 1. Ischemic cerebrovascular disease: Oral, 80-120 mg (4-6 tablets) per day, divided into 3 doses, for one month. 2. Migraine: Oral, 40 mg (2 tablets) once, 3 times a day, 12 weeks as a course of treatment, effective rate of 88%, about half of the cases can be basically cured or significantly effective, for vascular, tension, cluster and mixed headaches, etc. can reduce the pain, reduce the frequency and duration of attacks, and prevent the appearance of premonitory symptoms. 3. Cerebral vasospasm caused by subarachnoid hemorrhage: Oral, 40-60 mg (2-3 tablets) once, 3-4 times a day, 3-4 weeks as a course of treatment. For patients who need surgery, stop taking the medicine on the day of surgery, and continue to take it later. 4. Sudden deafness: Oral, 40-60 mg (2-3 tablets) per day, divided into 3 doses, 5 days as a course of treatment, generally 3-4 courses of treatment. 5. Mild and moderate hypertension: Patients with hypertension and the above-mentioned cerebrovascular diseases can be given priority. Oral administration, 40 mg (2 tablets) at a time, 3 times a day, the maximum daily dose is 240 mg (12 tablets).

A large number of clinical practices have shown that about 11.2% of patients with subarachnoid hemorrhage experience adverse reactions when treated with nimodipine. The most common adverse reactions are: 1. Decreased blood pressure, the degree of which is related to the drug dose. 2. Hepatitis. 3. Skin tingling. 4. Gastrointestinal bleeding. 5. Thrombocytopenia. 6. Occasionally, transient dizziness, headache, facial flushing, vomiting, gastrointestinal discomfort, etc. In addition, after oral administration of nimodipine, some patients may experience an increase in alkaline phosphatase (ALP), lactate dehydrogenase (LDH), AKP, an increase in blood sugar, and an increase in platelet count in some individuals.

Long-term use of antiepileptic drugs such as phenobarbital, phenytoin, and carbamazepine will significantly reduce the bioavailability of oral nimodipine, so it is not recommended to use this product and these antiepileptic drugs at the same time. If used to treat senile brain dysfunction, patients with severe liver dysfunction (such as cirrhosis) are prohibited from using nimodipine.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: 1. The drug can be secreted by breast milk, so it is not suitable for lactating women. 2. Animal experiments indicate that this product is teratogenic. Precautions for the elderly: Not yet clear.

Nimodipine is a Ca2 channel blocker. Under normal circumstances, the contraction of smooth muscle depends on the entry of Ca2 into the cell, causing the depolarization of the transmembrane current. Nimodipine achieves the purpose of relieving vasospasm by effectively preventing Ca2 from entering the cell and inhibiting the contraction of smooth muscle. Animal experiments have shown that the effect of nimodipine on cerebral arteries is much stronger than that on arteries in other parts of the body, and because it has a high lipophilic characteristic, it is easy to pass through the blood-brain barrier. When used for the treatment of subarachnoid hemorrhage, the concentration in cerebrospinal fluid can reach 12.5ng/ml. It can be inferred that it can be used clinically to prevent vasospasm after subarachnoid hemorrhage, but the mechanism of action of this drug in human application is still unclear. In addition, it also has the effect of protecting and promoting memory and promoting intellectual recovery. Therefore, it can selectively act on cerebral vascular smooth muscle, dilate cerebral blood vessels, increase cerebral blood flow, and significantly reduce ischemic brain damage caused by vasospasm.

Keep away from light, tightly closed and in a dry place.

30mg

36 months.

Hunan Baicao Pharmaceutical Co., Ltd.

• Founded in:

  1996-11-15

• Address:

  No. 808, Lingling North Road, Lengshuitan District, Yongzhou City

• Tax NO.:

  91431103188519962A

• Registered Funds:

  19.81 million yuan

• Website:

  Log in to view

• Email:

  Log in to view